由美国疾病控制与预防中心（CDC）资助的一项在几内亚比绍进行的新生儿乙肝疫苗试验因伦理争议和缺乏政府批准而被中止1。该试验由丹麦研究人员主导，试图研究乙肝疫苗是否会削弱其他活疫苗的益处1。
几内亚比绍卫生部长Quinhin Nantote否认该项目的推进1，研究人员Frederik Schaltz-Buchholzer也在领英发表声明称试验"不会在几内亚比绍推进"1。
这项耗资320万美元的试验由美国CDC和比尔·阿克曼支持的Pershing Square基金会等私人合作伙伴共同资助1，但遭到疫苗专家的强烈批评，他们认为该假设缺乏证据且在伦理上有问题1。疫苗专家Paul Offit表示："解决方案很清楚：拿钱给尽可能多的孩子接种"1。
几内亚比绍政府已收回研究人员的疫苗，建议将资金用于为新生儿普遍接种乙肝疫苗1。该国计划在2028年提供普遍出生剂量乙肝疫苗1。世卫组织建议所有婴儿在出生后尽快接种乙肝疫苗，最好在24小时内1。美国通过实施乙肝出生剂量项目，在启动该项目的几年内基本消除了儿童乙肝1。
A controversial clinical trial testing hepatitis B vaccination in newborns has been halted in Guinea-Bissau following ethical objections and lack of government authorization.1 The trial, funded with $3.2 million from the US Centers for Disease Control and Prevention and private partners including the Pershing Square Foundation backed by Bill Ackman, was led by Danish researchers seeking to investigate whether hepatitis B vaccines might reduce the benefits of other live vaccines.1 However, vaccine experts criticized the underlying hypothesis as lacking evidence and ethically problematic.1
Guinea-Bissau's government has reclaimed the vaccine supplies and rejected the project's continuation.1 Health Minister Quinhin Nantote denied the initiative would proceed in the country, and lead researcher Frederik Schaltz-Buchholzer stated on LinkedIn that the trial "will not move forward in Guinea-Bissau."1 Instead, the government plans to allocate resources toward providing universal hepatitis B vaccination at birth by 2028.1 Vaccine expert Paul Offit criticized the trial's premise, asserting that "the solution is clear: take the money and vaccinate as many children as possible."1 The World Health Organization recommends all infants receive hepatitis B vaccination as soon as possible after birth, ideally within 24 hours.1 The United States significantly reduced childhood hepatitis B cases within years of launching its own newborn hepatitis B vaccination program.1
评论
还没有评论，欢迎留下第一条。